Network toxicology and single-cell transcriptomics nominate candidate pyrethroid-associated targets and pathways in

Fu Wen1,2, Dan Wei2, Wencai Wang3

  • 1School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, China.

Insights

Pyrethroid insecticides may promote clear cell renal cell carcinoma (ccRCC) by increasing PNP and TYMS gene expression. This research identifies potential therapeutic targets for ccRCC linked to pyrethroid exposure.

Area of Science:

  • Toxicology
  • Oncology
  • Genomics

Background:

  • Pyrethroid insecticides are common in agriculture and homes.
  • Evidence links pyrethroid exposure to organ damage and potential cancer, but mechanisms for clear cell renal cell carcinoma (ccRCC) are unknown.

Purpose of the Study:

  • Investigate how common pyrethroids in household insecticides contribute to ccRCC development.
  • Identify core molecular targets and signaling pathways involved in pyrethroid-induced ccRCC.

Main Methods:

  • Integrated network toxicology, single-cell sequencing, and molecular docking.
  • Analyzed pyrethroid targets, ccRCC genes, and differential expression data (GSE36895).
  • Utilized machine learning to prioritize hub genes (PNP, TYMS) and assessed immune infiltration and single-cell transcriptomics.

Main Results:

  • Identified 50 overlapping genes between pyrethroid targets and ccRCC, enriched in chemokine signaling, cell adhesion, and p53 pathways.
  • PNP and TYMS were prioritized as key hub genes.
  • Pyrethroid compounds were shown to upregulate PNP and TYMS, promoting ccRCC development in vitro.

Conclusions:

  • PNP and TYMS are identified as candidate targets for pyrethroid insecticides in ccRCC.
  • This study provides a mechanistic basis for understanding pyrethroid-related ccRCC.
  • Findings may inform future targeted therapies for ccRCC associated with pyrethroid exposure.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...